background
cmvspecif
tcell
crucial
control
cmvreplic
posttranspl
regulatori
tcell
treg
associ
toler
immun
state
may
contribut
cmvreplic
howev
tcell
subset
treg
produc
tcell
well
studi
context
explor
treg
frequenc
cmvreplic
transplant
method
prospect
evalu
transplant
patient
cmvviremia
quantifi
cmvspecif
tcell
treg
frequenc
use
flowcytometri
follow
patient
requir
antivir
treatment
two
subset
compar
antivir
treatment
requir
n
vs
spontan
clearanc
viremia
n
result
higher
initi
cmvspecif
tcell
lower
treg
observ
patient
spontan
clearanc
p
p
respect
use
ratio
cmvspecif
tcell
treg
allow
predict
viral
clearanc
sensit
specif
p
one
month
stop
treatment
correl
observ
patient
protect
cmvrelaps
ratio
cmvspecif
tcell
treg
allow
predict
relaps
sensit
specif
p
respons
correl
virolog
outcom
conclus
studi
provid
novel
insight
treg
subpopul
cmvreplic
transplant
preliminari
data
suggest
measur
cmvspecif
tcell
togeth
treg
valu
predict
spontan
clearanc
viremia
relaps
solid
organ
transplant
cytomegaloviru
cmv
replic
may
result
viral
syndrom
tissu
invas
diseas
cmvreplic
may
also
play
role
acut
chronic
allograft
injuryreject
impair
longterm
graft
outcom
increas
rate
bacteri
fungal
infect
mechan
effect
occur
incomplet
character
posttranspl
set
adapt
immun
respons
specif
tcell
respons
play
promin
role
control
cmv
replic
decreas
cmvspecif
tcell
associ
progress
cmvreplic
recent
addit
tcell
subset
recogn
import
role
exampl
intern
regulatori
mechan
regulatori
tcell
treg
may
modifi
cmvspecif
tcell
function
lead
increas
risk
progress
cmvreplic
treg
primarili
function
releas
inhibitori
cytokin
tgfb
treg
play
import
role
maintain
selftoler
studi
potenti
mean
promot
immunotoler
state
posttranspl
follow
liver
transplant
high
frequenc
treg
peripher
blood
hepat
tissu
associ
aggress
recurr
hepat
c
viru
produc
tcell
newli
describ
subtyp
tcell
constitut
part
normal
host
respons
infect
due
proinflammatori
effect
cell
also
associ
allograft
reject
autoimmun
diseas
precis
role
respons
cmvreplic
well
elucid
although
recent
studi
suggest
variou
viral
infect
murin
cmv
influenza
viru
herp
simplex
viru
induc
respons
follow
transplant
patient
typic
monitor
molecular
diagnost
tool
detect
cmvreplic
earli
stage
kinet
viru
replic
howev
weakli
associ
futur
outcom
progress
replic
develop
tissueinvas
diseas
novel
immunolog
biomark
virusspecif
tcell
respons
might
bridg
gap
knowledg
full
repertoir
tcell
respons
includ
absolut
treg
subset
studi
transplant
recipi
activ
cmvreplic
hypothes
follow
transplant
signific
alter
occur
treg
dynam
set
cmvreplic
present
studi
aim
prospect
assess
cmvspecif
tcell
total
treg
frequenc
transplant
recipi
concurr
cmvreplic
immunolog
paramet
assess
simultan
clinic
paramet
cmv
viralload
kinet
clearanc
relaps
rate
aim
use
marker
predict
clearanc
onset
viremia
relaps
stop
treatment
studi
approv
univers
alberta
ethic
review
board
patient
provid
written
inform
consent
adult
solid
organ
transplant
patient
cmvreplic
defin
viremia
copiesml
plasma
prospect
identifi
enrol
blood
sampl
immunolog
assay
collect
within
three
day
detect
viral
replic
patient
commenc
antivir
treatment
underw
followup
blood
sampl
regular
time
interv
see
figur
start
treatment
initi
sampl
drawn
time
first
viremia
detect
unless
later
followup
antivir
treatment
requir
clinic
outcom
followup
data
collect
minimum
six
month
postenrol
decis
use
antivir
treatment
type
therapi
use
discret
treat
physician
manag
patient
guid
local
institut
protocol
patient
lowlevel
viremia
copi
ml
manag
surveil
without
antivir
treatment
patient
symptom
higher
viralload
receiv
antivir
therapi
either
intraven
ganciclovir
oral
valganciclovir
resolut
viremia
definit
cmvdiseas
base
recommend
use
clinic
studi
includ
viral
syndrom
tissu
invas
diseas
virolog
relaps
defin
clearanc
initi
viremia
follow
subsequ
detect
viru
least
two
separ
occas
patient
minimum
increas
viralload
treatment
clinic
sign
symptom
relaps
assess
minimum
six
month
initi
episod
diseas
cmv
viralload
test
perform
plasma
sampl
use
inhous
realtim
lightcycl
base
pcr
assay
valid
clinic
use
assay
dna
extract
ml
plasma
amplifi
use
primer
target
conserv
region
glycoprotein
b
gene
cmv
detect
achiev
use
fluoresc
probe
previous
describ
see
ref
primer
probe
sequenc
assay
lower
limit
quantif
copiesml
dynam
rang
approxim
copi
valid
commerci
avail
coba
amplicor
cmv
monitor
assay
initi
detect
patient
weekli
viralload
test
perform
patient
commenc
antivir
treatment
individu
viral
kinet
calcul
perform
viralload
plot
time
bestfit
exponenti
decay
curv
appli
gener
appropri
mathemat
descript
virolog
outcom
slope
decay
curv
calcul
base
bestfit
line
context
neg
decay
slope
rapid
viral
clearanc
posit
initi
decay
slope
indic
increas
viralload
coincid
initi
treatment
cellular
immun
respons
patient
commenc
antivir
measur
three
timepoint
onset
viremia
synonym
initi
antivir
therapi
end
treatment
one
month
treatment
complet
patient
receiv
antivir
therapi
tcell
respons
measur
onset
viremia
quantifi
cmvspecif
tcell
accord
previous
publish
protocol
slight
modif
briefli
peripher
blood
mononuclear
cell
pbmc
isol
whole
blood
use
ficollpaqu
pharmacia
uppsala
sweden
gradient
densiti
centrifug
store
liquid
nitrogen
use
determin
cmvspecif
tcell
respons
pbmc
stimul
hour
peptid
pool
librari
cover
entir
immedi
protein
peptid
amino
acid
overlap
final
concentr
mgml
dmso
jpt
technolog
berlin
germani
dmso
concentr
experi
maintain
less
cmvspecif
tcell
respons
pbmc
stimul
hour
cmv
whole
viru
lysat
deriv
fibroblast
cultur
advanc
biotechnolog
inc
columbia
md
concentr
mg
ml
select
type
stimul
peptid
vs
viral
lysat
concentr
use
durat
stimul
base
valid
studi
perform
use
cmv
seroposit
seroneg
healthi
volunt
optim
assay
found
viral
lysat
optimum
stimul
cell
wherea
peptid
pool
optim
stimul
tcell
also
support
literatur
use
posit
control
media
alon
serv
neg
control
two
hour
follow
stimul
brefeldin
final
concentr
mgml
ad
block
interferongamma
ifnc
secret
next
pbmc
underw
cell
surfac
stain
follow
fixat
membran
perfor
use
standard
buffer
ebiosci
intracellular
stain
perform
follow
fluoresc
monoclon
antibodi
use
antihuman
allophycocyaninefluor
tm
antihuman
alpha
chain
peantihuman
interferongamma
ifnc
ebiosci
inc
san
diego
ca
isotyp
antibodi
use
appropri
treg
defin
tcell
use
antihuman
apc
antihuman
pe
cell
identifi
tcell
use
antihuman
pe
product
induc
h
stimul
pma
phorbol
myrist
acet
ionomycin
final
concentr
mgml
ngml
respect
co
previous
publish
flow
data
acquir
use
bd
facsarray
tm
bioanalyz
system
equip
facsarray
tm
system
softwar
result
analyz
use
fc
express
version
de
novo
softwar
lo
angel
ca
usa
tcell
obtain
per
sampl
statist
analysi
cmvspecif
tcell
respons
express
amount
ifnc
produc
tcell
percentag
total
tcell
subtract
respect
neg
control
cmvspecif
tcell
respons
express
manner
treg
tcell
cell
produc
tcell
express
percentag
total
tcell
respons
cmvspecif
tcell
consid
significantli
differ
neg
control
base
calcul
two
standard
deviat
mean
neg
control
valu
statist
analys
perform
use
spss
version
chicago
ill
graphpad
prism
version
la
jolla
ca
fisher
exact
test
chisquar
test
use
categor
variabl
mannwhitney
u
test
use
continu
variabl
correl
perform
use
spearman
correl
coeffici
alpha
set
equal
test
signific
two
tail
clinic
demograph
characterist
enrol
patient
list
tabl
total
patient
enrol
includ
patient
highlevel
viremia
andor
symptomat
cmvdiseas
requir
commenc
antivir
therapi
group
compar
patient
asymptomat
lowlevel
viremia
spontan
clear
cmv
viremia
without
treatment
median
time
cmvreplic
posttranspl
day
rang
day
major
patient
receiv
immunosuppress
calcineurin
inhibitor
tacrolimu
cyclosporin
prednison
mycophenol
mofetil
mmf
time
initi
cmv
detect
patient
sirolimu
tabl
previou
anticmv
prophylaxi
administ
patient
patient
biopsi
proven
acut
reject
within
threemonth
period
followup
initi
detect
cmv
statist
signific
differ
cmv
serolog
statu
present
patient
group
higher
percentag
patient
progress
viremia
group
vs
spontan
clearanc
group
vs
p
although
statist
signific
signific
differ
type
immunosuppress
transplant
organ
observ
two
group
p
ns
ten
patient
spontan
clear
cmvviremia
median
viralload
baselin
patient
log
copiesml
rang
log
copiesml
median
time
viral
clearanc
day
rang
day
twenti
patient
receiv
antivir
therapi
follow
viralclear
kinet
observ
median
viralload
baselin
log
copiesml
rang
log
copiesml
median
time
clearanc
day
rang
day
one
patient
achiev
complet
clearanc
viremia
despit
prolong
antivir
therapi
seven
patient
relaps
detect
cmvviremia
followup
period
baselin
cmvspecif
tcell
respons
determin
patient
onset
viremia
patient
also
timepoint
treatment
initi
median
fraction
cmvspecif
tcell
total
cohort
rang
n
rang
n
respect
patient
show
initi
posit
cmvspecif
tcell
respons
wherea
patient
show
initi
posit
cmvspecif
tcell
respons
patient
cmv
diseaseprogress
viremia
significantli
lower
initi
cmvspecif
tcell
frequenc
compar
patient
spontan
clearanc
viremia
vs
p
figur
receiv
oper
characterist
roc
curv
made
determin
potenti
clinic
util
assay
predict
clinic
outcom
figur
outcom
analyz
spontan
clearanc
viremia
vs
progress
relaps
viremia
complet
treatment
outcom
differ
cutoff
defin
posit
tcell
measur
analyz
sensit
specif
tcell
roc
analysi
reveal
cutoff
cmvspecif
tcell
could
predict
spontan
clearanc
viremia
sensit
specif
auc
p
figur
initi
level
cmvspecif
tcell
also
predict
subsequ
viralload
dynam
initi
cmvspecif
tcell
frequenc
correl
significantli
cmv
viral
kinet
day
express
slope
viral
declin
r
p
trend
observ
initi
cmvspecif
tcell
count
subsequ
viralload
ie
two
week
later
logist
regress
r
p
patient
requir
antivir
therapi
immunolog
monitor
point
treatment
discontinu
one
month
later
determin
immunolog
risk
marker
predict
relaps
stop
treatment
median
cmvspecif
tcell
frequenc
treatment
discontinu
month
later
rang
rang
respect
relaps
cmvviremia
occur
patient
median
day
follow
complet
antivir
therapi
virolog
relaps
symptomat
asymptomat
patient
patient
cmvrelaps
display
significantli
lower
cmvspecif
tcell
count
one
month
treatment
discontinu
compar
patient
without
relaps
vs
p
figur
tabl
roc
analysi
reveal
cutoff
cmvspecif
tcell
could
predict
relaps
sensit
specif
auc
p
figur
patient
without
relaps
exhibit
consist
increas
cmvspecif
tcell
followup
period
respect
wherea
patient
cmvrelaps
opposit
observ
respect
figur
baselin
treg
percentag
patient
median
rang
baselin
treg
frequenc
significantli
higher
patient
progress
viremia
compar
spontan
clearanc
viremia
median
vs
respect
p
figur
roc
analysi
reveal
cutoff
treg
predict
spontan
clearanc
viremia
sensit
specif
auc
p
figur
interestingli
initi
treg
count
significantli
associ
viralload
measur
two
week
later
logist
regress
r
p
addit
strong
associ
observ
initi
treg
frequenc
slope
viral
kinet
respons
day
r
median
treg
treatment
discontinu
month
later
rang
rang
respect
patient
relaps
cmv
significantli
higher
treg
count
one
month
stop
treatment
compar
patient
without
relaps
vs
p
figur
tabl
signific
correl
observ
concurr
measur
cmvspecif
tcell
treg
frequenc
p
ns
spearman
rho
use
combin
cmvspecif
tcell
treg
significantli
increas
sensit
specif
predict
clearanc
relaps
ratio
cmvspecif
tcell
treg
tcell
treg
could
predict
spontan
clearanc
viremia
sensit
specif
auc
p
figur
addit
one
month
antivir
discontinu
ratio
cmvspecif
tcell
treg
tcell
treg
highli
predict
relaps
auc
p
figur
baselin
median
popul
patient
rang
differ
frequenc
observ
patient
spontan
clearanc
viremia
progress
viremia
p
ns
figur
addit
differ
observ
relat
relaps
cmv
frequenc
cell
slightli
reduc
one
month
treatment
discontinu
median
p
ns
studi
analyz
cmvspecif
tcell
conjunct
treg
frequenc
prospect
assess
context
viral
kinet
monitor
two
differ
subgroup
patient
cmvreplic
group
high
viralload
commenc
antivir
treatment
vs
group
spontan
clearanc
viremia
found
cmvspecif
tcell
total
treg
significantli
associ
spontan
clearanc
viremia
well
protect
relaps
immun
marker
use
combin
enabl
predict
virolog
outcom
sensit
specif
addit
cell
stabli
express
correl
virolog
outcom
roc
curv
analysi
use
determin
cutoff
predict
diseas
optim
sensit
specif
found
best
predictor
spontan
clearanc
viremia
relaps
treatment
frequenc
ratio
cmv
cell
treg
area
curv
approach
highli
signific
futur
valid
done
use
cutoff
valu
sever
studi
analyz
predict
valu
cmvspecif
tcell
regard
develop
progress
cmvreplic
diseas
conclud
reduct
frequenc
cell
associ
increas
risk
cmvreplic
studi
observ
correl
cmvspecif
tcell
respons
virolog
outcom
may
due
high
proport
r
patient
cohort
cmvspecif
tcell
respons
shown
promin
r
patient
primari
infect
howev
r
patient
data
role
cell
cmv
control
consist
previou
studi
illustr
import
cmvspecif
tcell
longterm
control
cmv
r
patient
egli
et
al
report
high
tcell
respons
kidney
transplant
patient
associ
lower
risk
concurr
futur
cmvreplic
eightweek
period
follow
analysi
sester
et
al
determin
cmvlysat
specif
tcell
protect
cmvreplic
studi
found
cmvspecif
tcell
greater
associ
spontan
resolut
viremia
whilst
valu
one
month
treatment
discontinu
associ
increas
risk
relaps
posit
correl
also
found
frequenc
cmvspecif
tcell
speed
viral
decay
stabl
cmvspecif
tcell
respons
associ
control
late
cmv
reactiv
transplant
recpient
wherea
cmvspecif
tcell
seem
import
primari
infect
earli
phase
transplant
increas
frequenc
treg
observ
varieti
infecti
condit
occur
acut
infect
predominantli
observ
chronic
viral
infect
chronic
infect
treg
may
play
two
potenti
role
benefici
role
limit
collater
tissu
damag
detriment
role
impair
antivir
immun
respons
virusspecif
treg
rare
examin
like
whole
treg
popul
contain
least
virusspecif
cell
popul
probabl
gener
parallel
virusspecif
effector
tcell
respons
concept
recent
illustr
coronaviru
infect
model
may
repres
mechan
serv
protect
excess
immun
respons
post
exposur
acut
viral
infect
model
provid
support
propos
role
treg
limit
immunemedi
patholog
eg
west
nile
viru
respiratori
syncyti
viru
influenza
viru
replic
increas
treg
number
would
expect
lead
impair
clearanc
infect
pathogen
evid
hypothesi
found
sever
model
mainli
chronic
viral
infect
carpenti
et
al
show
follow
liver
transplant
patient
high
treg
frequenc
like
aggress
hcv
recurr
mous
model
herp
simplex
viru
associ
retin
treg
associ
progress
sever
tissu
invas
diseas
role
treg
control
cmvspecif
immun
respons
recent
examin
blood
sampl
obtain
healthi
donor
transplant
recipi
deplet
treg
cell
figur
outcom
relaps
cmv
complet
treatment
n
follow
three
test
analyz
cmvspecif
tcell
respons
figur
treg
respons
figur
ratio
cmvspecif
tcell
treg
respons
figur
determin
sensit
specif
predict
clearanc
viremia
use
baselin
immun
measur
predict
relaps
use
measur
one
month
complet
treatment
pbmc
result
enhanc
cmvspecif
tcell
respons
vitro
accumul
virusspecif
treg
viru
replic
could
due
expans
preexist
popul
thymusderiv
natur
treg
specif
viral
antigen
could
also
reflect
de
novo
gener
induc
treg
naiv
virusspecif
cell
import
factor
gener
induc
treg
appear
tgfb
limit
vitro
data
role
cmvprotein
regul
treg
gener
cocultur
model
tcell
murinecmv
infect
fibroblast
upregul
tgfb
express
observ
subsequ
induc
tcell
differenti
treg
studi
unabl
answer
detail
question
whether
cmvreplic
influenc
treg
develop
function
nevertheless
observ
correl
treg
frequenc
baselin
viralload
quantif
ensu
two
week
r
would
suggest
treg
may
play
import
role
regul
cmvreplic
role
respons
viral
infect
poorli
character
virusspecif
tcell
detect
mice
follow
infect
murinecmv
herp
simplex
viru
influenza
viru
gener
polar
cell
viral
infect
correl
high
level
may
also
influenc
transform
growth
factorb
tgfb
cell
implic
drive
harm
inflamm
autoimmun
may
contribut
immunopatholog
host
respons
virus
studi
find
cell
frequenc
correl
cmv
outcom
studi
sever
limit
first
sampl
size
small
includ
heterogen
popul
solid
organ
transplant
recipi
tri
minim
effect
studi
two
distinct
group
patient
requir
antivir
treatment
compar
spontan
clear
viremia
howev
result
confirm
larger
subset
patient
studi
consid
preliminari
sinc
effect
cofactor
transplant
type
immunosuppress
regimen
dr
serostatu
may
appar
larger
sampl
size
factor
signific
predictor
outcom
group
although
immunosuppress
use
rel
homogen
studi
patient
cmv
diseas
neither
dr
statu
transplant
type
effect
viremia
clearanc
intens
immunosuppress
modest
effect
time
viral
clearanc
show
associ
overal
clearanc
rate
recurr
secondli
would
interest
measur
cmvspecif
tregulatori
cmvspecif
cell
unfortun
frequenc
cell
low
peripher
blood
vitro
cultiv
could
well
gener
expans
bia
thirdli
precis
effect
treg
cmvspecif
tcell
assess
variou
way
chose
evalu
frequenc
cmvspecif
tcell
use
interferon
gamma
predomin
cytokin
produc
respons
specif
stimul
product
background
use
identifi
respons
virusspecif
tcell
howev
function
impact
treg
could
primarili
affect
marker
interleukin
tcell
prolifer
despit
limit
studi
provid
novel
insight
treg
cell
dynam
transplant
recipi
activ
cmvreplic
cmvspecif
tcell
dynam
analyz
conjunct
virolog
paramet
clinic
outcom
treg
frequenc
elev
patient
develop
cmvdiseas
compar
spontan
clear
cmvviremia
high
cmvspecif
tcell
low
treg
count
significantli
associ
clearanc
viremia
protect
relaps
larger
multicent
studi
requir
explor
predict
valu
cmvspecif
tcell
treg
monitor
transplant
may
help
individu
patient
manag
immun
monitor
could
differenti
patient
risk
cmvreplic
protect
therebi
inform
critic
treatment
decis
reduc
morbid
ultim
preserv
graft
function
figur
studi
design
patient
enrol
immun
monitor
within
day
detect
cmvreplic
initi
timepoint
cmvspecif
tcell
measur
well
absolut
frequenc
tregulatori
cell
produc
tcell
patient
commenc
antivir
treatment
measur
immun
marker
end
antivir
treatment
month
later
